China Pharma Holdings (CPHI) Receivables - Other (2016 - 2025)
China Pharma Holdings' Receivables - Other history spans 15 years, with the latest figure at $49261.0 for Q4 2025.
- For Q4 2025, Receivables - Other rose 62.65% year-over-year to $49261.0; the TTM value through Dec 2025 reached $49261.0, up 62.65%, while the annual FY2025 figure was $49261.0, 62.65% up from the prior year.
- Receivables - Other reached $49261.0 in Q4 2025 per CPHI's latest filing, down from $61275.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $1.7 million in Q3 2021 to a low of $28660.0 in Q2 2024.
- Average Receivables - Other over 5 years is $523462.9, with a median of $55268.0 recorded in 2025.
- Peak YoY movement for Receivables - Other: crashed 97.96% in 2022, then skyrocketed 442.04% in 2023.
- A 5-year view of Receivables - Other shows it stood at $1.4 million in 2021, then plummeted by 97.96% to $29139.0 in 2022, then surged by 442.04% to $157944.0 in 2023, then plummeted by 80.82% to $30286.0 in 2024, then skyrocketed by 62.65% to $49261.0 in 2025.
- Per Business Quant, the three most recent readings for CPHI's Receivables - Other are $49261.0 (Q4 2025), $61275.0 (Q3 2025), and $48361.0 (Q2 2025).